Latest News
24 November 2015 Half year results: Delivery, acquisition and growth Read More
Upcoming Events
7-10 December 2015 Antibody Engineering and Therapeutics
San Deigo, USA
10 December 2015 Genesis
London, UK
18-22 January 2016 PepTalk
San Diego, CA, USA

On 24 November 2015, Abzena plc agreed to acquire TCRS, a specialist contract chemistry and bioconjugation company. The acquisition is an important strategic step to build Abzena into a self-sustaining business and ‘partner of choice’ for R&D organisations. For more information, see the press release.

Abzena has also announced its half year results for the six months ended 30 September. For more information, see the press release.

Abzena offers a suite of complementary services and technologies through its subsidiaries, PolyTherics, Antitope and PacificGMP, to enable the development of better biopharmaceuticals which will have a greater chance of reaching the market.

Privacy & cookie policy
© Abzena plc, 2014. All rights reserved.